Should You Buy Arcturus Therapeutics Holdings Inc (ARCT) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/28
ARCT is not a good buy right now for a Beginner long-term investor with $50k–$100k, because the setup is still largely catalyst-dependent (rare-disease clinical/regulatory milestones) while near-term visibility is limited (no fresh news flow and a previously noted U.S. BLA path delayed). Even though the stock trades around the cash-value narrative and has upside if programs advance, the current entry does not offer a clear, high-conviction long-term buy signal today. My call: HOLD (only consider buying if you specifically want high-risk biotech exposure and can accept a bumpy path into 1H 2026).
Technical Analysis
Pre-market ~7.61 (+2.01%) places ARCT just above the pivot (7.444), indicating a slightly constructive near-term posture but not a breakout. MACD histogram is positive (0.093) but contracting, which suggests bullish momentum is fading rather than accelerating. RSI(6) ~57.96 is neutral-to-slightly bullish without being overbought. Moving averages are converging, consistent with consolidation. Key levels: support S1 7.069 then S2 6.838; resistance R1 7.818 then R2 8.049. A decisive move and hold above ~7.82–8.05 would improve trend conviction; failure would likely mean a retest of ~7.07.
Analyst Ratings and Price Target Trends
Recent trend is mixed: Citi stayed Neutral while cutting PTs (to $9 in Nov 2025, then to $7 in Jan 2026), reflecting tempered expectations. Roth initiated coverage on 2026-01-22 with a Buy and $20 PT, emphasizing mispricing vs cash and mid-stage asset potential. Piper (Overweight) dramatically reduced its PT (to $72 from $140) after Q3 updates, highlighting the delayed U.S. BLA for KOSTAIVE and pointing to 1H 2026 as an inflection period for ARCT-810/ARCT-032. Wall Street pros: significant upside if rare-disease programs deliver and valuation re-rates from “cash-like.” Cons: reduced near-term commercial visibility and repeated PT cuts from at least one major bank, keeping sentiment divided.
Wall Street analysts forecast ARCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARCT is 30.57 USD with a low forecast of 7 USD and a high forecast of 72 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast ARCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARCT is 30.57 USD with a low forecast of 7 USD and a high forecast of 72 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 7.570
Current: 7.570
